These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1414 related items for PubMed ID: 31338731

  • 1. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
    Schmidkonz C, Cordes M, Goetz TI, Prante O, Kuwert T, Ritt P, Uder M, Wullich B, Goebell P, Bäuerle T.
    Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
    [Abstract] [Full Text] [Related]

  • 2. 68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer.
    Schmidkonz C, Cordes M, Schmidt D, Bäuerle T, Goetz TI, Beck M, Prante O, Cavallaro A, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P.
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1862-1872. PubMed ID: 29725716
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.
    Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, Scarpa L, di Santo G, Roig LG, Maffey-Steffan J, Horninger W, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
    [Abstract] [Full Text] [Related]

  • 8. (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.
    Sachpekidis C, Eder M, Kopka K, Mier W, Hadaschik BA, Haberkorn U, Dimitrakopoulou-Strauss A.
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1288-99. PubMed ID: 26753602
    [Abstract] [Full Text] [Related]

  • 9. PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer.
    Verburg FA, Pfister D, Drude NI, Mottaghy FM, Behrendt FF.
    Nuklearmedizin; 2017 Jul; 56(6):225-232. PubMed ID: 29044297
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Total-Body 68Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines.
    Pomykala KL, Czernin J, Grogan TR, Armstrong WR, Williams J, Calais J.
    J Nucl Med; 2020 Mar; 61(3):405-411. PubMed ID: 31541035
    [Abstract] [Full Text] [Related]

  • 12. Factors Predicting Metastatic Disease in 68Ga-PSMA-11 PET-Positive Osseous Lesions in Prostate Cancer.
    Chiu LW, Lawhn-Heath C, Behr SC, Juarez R, Perez PM, Lobach I, Bucknor MD, Hope TA, Flavell RR.
    J Nucl Med; 2020 Dec; 61(12):1779-1785. PubMed ID: 32303599
    [Abstract] [Full Text] [Related]

  • 13. 68Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer.
    Sachpekidis C, Bäumer P, Kopka K, Hadaschik BA, Hohenfellner M, Kopp-Schneider A, Haberkorn U, Dimitrakopoulou-Strauss A.
    Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):904-912. PubMed ID: 29362859
    [Abstract] [Full Text] [Related]

  • 14. Combined Early and Late [68Ga]PSMA-HBED-CC PET Scans Improve Lesion Detectability in Biochemical Recurrence of Prostate Cancer with Low PSA Levels.
    Hohberg M, Kobe C, Täger P, Hammes J, Schmidt M, Dietlein F, Wild M, Heidenreich A, Drzezga A, Dietlein M.
    Mol Imaging Biol; 2019 Jun; 21(3):558-566. PubMed ID: 30105521
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of whole-body tumor burden with 68Ga-PSMA PET/CT in the biochemical recurrence of prostate cancer.
    Brito AET, Mourato FA, de Oliveira RPM, Leal ALG, Filho PJA, de Filho JLL.
    Ann Nucl Med; 2019 May; 33(5):344-350. PubMed ID: 30746599
    [Abstract] [Full Text] [Related]

  • 16. Correlations of the 68Ga-PSMA PET/CT derived primary prostate tumor PSMA expression parameters and metastatic patterns in patients with Gleason Score >7 prostate cancer.
    Karyagar SS, Karyagar S, Guven O.
    Hell J Nucl Med; 2020 May; 23(2):120-124. PubMed ID: 32716402
    [Abstract] [Full Text] [Related]

  • 17. Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer.
    Freitag MT, Radtke JP, Hadaschik BA, Kopp-Schneider A, Eder M, Kopka K, Haberkorn U, Roethke M, Schlemmer HP, Afshar-Oromieh A.
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):70-83. PubMed ID: 26508290
    [Abstract] [Full Text] [Related]

  • 18. The role of (68Ga)PSMA I&T in biochemical recurrence after radical prostatectomy: detection rate and the correlation between the level of PSA, Gleason score, and the SUVmax.
    Yilmaz U, Komek H, Can C, Altindag S.
    Ann Nucl Med; 2019 Aug; 33(8):545-553. PubMed ID: 31069696
    [Abstract] [Full Text] [Related]

  • 19. 68Ga-PSMA-HBED-CC PET/CT imaging in Black versus White South African patients with prostate carcinoma presenting with a low volume, androgen-dependent biochemical recurrence: a prospective study.
    Lengana T, van de Wiele C, Lawal I, Maes A, Ebenhan T, Boshomane T, Zeevaart JR, Ankrah A, Mokgoro N, Vorster M, Sathekge M.
    Nucl Med Commun; 2018 Feb; 39(2):179-185. PubMed ID: 29257006
    [Abstract] [Full Text] [Related]

  • 20. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 71.